- Home
- MCRB vs JHI Comparison
MCRB vs JHI Comparison
Compare MCRB & JHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- JHI
- Stock Information
- Founded
- MCRB 2010
- JHI 1971
- Country
- MCRB United States
- JHI United States
- Employees
- MCRB N/A
- JHI N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- JHI Trusts Except Educational Religious and Charitable
- Sector
- MCRB Health Care
- JHI Finance
- Exchange
- MCRB Nasdaq
- JHI Nasdaq
- Market Cap
- MCRB 131.0M
- JHI 124.3M
- IPO Year
- MCRB 2015
- JHI N/A
- Fundamental
- Price
- MCRB $0.73
- JHI $14.09
- Analyst Decision
- MCRB Buy
- JHI
- Analyst Count
- MCRB 4
- JHI 0
- Target Price
- MCRB $5.63
- JHI N/A
- AVG Volume (30 Days)
- MCRB 2.0M
- JHI 29.5K
- Earning Date
- MCRB 03-04-2025
- JHI 01-01-0001
- Dividend Yield
- MCRB N/A
- JHI 6.80%
- EPS Growth
- MCRB N/A
- JHI N/A
- EPS
- MCRB N/A
- JHI 1.05
- Revenue
- MCRB $126,325,000.00
- JHI N/A
- Revenue This Year
- MCRB N/A
- JHI N/A
- Revenue Next Year
- MCRB N/A
- JHI N/A
- P/E Ratio
- MCRB N/A
- JHI $12.47
- Revenue Growth
- MCRB 12856.41
- JHI N/A
- 52 Week Low
- MCRB $0.54
- JHI $11.63
- 52 Week High
- MCRB $1.53
- JHI $13.40
- Technical
- Relative Strength Index (RSI)
- MCRB 37.88
- JHI 57.83
- Support Level
- MCRB $0.71
- JHI $13.84
- Resistance Level
- MCRB $0.91
- JHI $14.17
- Average True Range (ATR)
- MCRB 0.06
- JHI 0.11
- MACD
- MCRB -0.02
- JHI 0.04
- Stochastic Oscillator
- MCRB 8.37
- JHI 84.62
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.